ARCHIVES

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

DCPC Advisors Approve Five New RFA concepts, Set Aside $33.6 Million

June 4, 1993

A Conversation With Daniel Masys: Acronym “CABIG” Could Be Eliminated

January 6, 2012

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

Decision On New Division Two-Three Weeks Away: Upton

August 17, 1979

NCI RFA: Tobacco Use Research Centers

December 18, 1998

Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival

June 24, 2011